GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN A) » Definitions » Future 3-5Y EPS without NRI Growth Rate

H. Lundbeck AS (OCSE:HLUN A) Future 3-5Y EPS without NRI Growth Rate : 7.83 (As of Sep. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, H. Lundbeck AS's Future 3-5Y EPS without NRI Growth Rate is 7.83.

Competitive Comparison of H. Lundbeck AS's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

H. Lundbeck AS's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Future 3-5Y EPS without NRI Growth Rate falls into.


H. Lundbeck AS  (OCSE:HLUN A) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

H. Lundbeck AS Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN A) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ SZSE:000538 BOM:500124 BOM:532321 TSE:4523 HKSE:03692 BOM:543904 NSE:DIVISLAB NSE:TORNTPHARM CTLT
Traded in Other Exchanges
HLBBF:USA HLUBF:USA 0ABR:UK 0ND5:UK HLUN B:Denmark LDBA:Germany
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines